Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
No biomarker
Cancer:
Vulvar Cancer
Regimen:
(cisplatin + gemcitabine)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
NCCN
Published date:
04/26/2021
Excerpt:
Vulvar cancer (Squamous cell carcinoma): Advanced or recurrent/metastatic disease…Other recommended regimens…Cisplatin/gemcitabine (category 2B)
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login